Person: BÜYÜKAYDIN, BANU
4 results
Search Results
Now showing 1 - 4 of 4
Publication Metadata only Orthostatic Hypotension in Older Adults(2021-01-01T00:00:00Z) Büyükaydın, Banu; Kazancıoğlu, Rümeyza; BÜYÜKAYDIN, BANU; KAZANCIOĞLU, RÜMEYZAPublication Metadata only The impact of obesity on acute pancreatitis outcomes in older patients(2020-03-01T00:00:00Z) Büyükaydın, Banu; Yabacı, Ayşegül; Kiremitçi, Sercan; Soysal, Pınar; Biberci Keskin, Elmas; Şentürk, Hakan; BİBERCİ KESKİN, ELMAS; BÜYÜKAYDIN, BANU; SOYSAL, PINAR; YABACI TAK, AYŞEGÜL; ŞENTÜRK, HAKANAimThe aim of this study was to investigate the impact of obesity on acute pancreatitis outcomes in older patients.FindingsObesity in older patients with acute pancreatitis was not associated with worse outcomes, including in-hospital mortality, long-term mortality, and recurrence.MessageThe impact of obesity in older people with acute pancreatitis may not be as deleterious as seen in younger patients.AbstractPurposeAlthough obesity is an established risk factor for a number of diseases, several epidemiological studies have demonstrated that older obese patients have better survival rates than non-obese old patients in various disease states. In this context, the relationship between obesity and acute pancreatitis outcome in older patients is controversial. Therefore, the authors aimed to investigate the impact of obesity on acute pancreatitis outcomes in older patients.MethodsPatients aged > 65years who had been hospitalized for acute pancreatitis were retrospectively analyzed. Among them, 190 patients were included. The median age was 73 (68–79) years, and 118 (62.1%) were women. Obesity was assessed according to body mass index, and patients were classified as either obese or non-obese. The primary endpoint of the study was in-hospital major adverse events (major in-hospital complications and death). The secondary endpoints were acute pancreatitis recurrence, 30-day all-cause mortality, and long-term all-cause mortality.ResultsA total of 77 (40.5%) patients were obese. In-hospital major adverse events were observed in 40 (21.1%) patients. There was no statistical difference in major in-hospital adverse events between the two groups (27 [23.9%] in non-obese patients vs. 13 [16.9%] in obese patients,p = 0.24). Further, the 30-day mortality, long-term survival, and acute pancreatitis recurrence rates were similar (allp > 0.05). The median follow-up time was 18 (0–80) months.ConclusionObesity does not result in higher mortality or complications in older patients with acute pancreatitis. Although the underlying mechanism needs to be elucidated, the deleterious effect of obesity seems to be diminished in older patients.Publication Metadata only The changes of oxidative stress markers and vitamin E in patients with diabetes using SGLT2 inhibitors(2023-01-01) Buyukaydin B.; ÖZER Ö. F.; ÖZDER A.; YILDIZ C.; BÜYÜKAYDIN, BANU; ÖZER, ÖMER FARUK; ÖZDER, ACLAN; YILDIZ, CANERObjectives: This study aimed to research the diversities of vitamin E and oxidative stress parameters related to sodium-glucose transport protein 2 (SGLT2) inhibitor use by type 2 diabetes mellitus (T2DM) patients. Methods: This observational clinical study collected data from 67 T2DM patients (55.7±9.3 years, 46% female). Vitamin E, total oxidant status (TOS), total antioxidant status (TAS), total thiol, native thiol, myeloperoxidase, and catalase levels were evaluated. The TOS/TAS ratio was calculated as the oxidative stress index. Correlations of the parameters to each other and differences based on SGLT2 inhibitor use were recorded. Results: The mean hemoglobin A1c was 7.1 (5.5–13.1). SGLT2 inhibitors (all combinations) were used by 25 patients (37.3%). The mean level of vitamin E was 6 (3.6–9.8) mg/L. There was a positive correlation between vitamin E and low-density lipoprotein cholesterol (p<0.001). While there was no significant correlation between vitamin E and all included oxidative stress parameters, the level of vitamin E was statistically lower in patients using pioglitazone (p=0.036) and statins (p<0.001). In patients using SGLT2 inhibitors, fasting glucose, triglycerides, alanine aminotransferase, and the spot urine protein/creatinine ratio were significantly lower, and the mean TAS was higher (p<0.05). Conclusion: While no differences were observed in vitamin E and other oxidative parameters related to SGLT2 inhibitor use, the increase in TAS provides motivation for further research investigating the antioxidant properties of these inhibitors.Publication Metadata only Evaluation of risk scores as predictors of mortality and hospital length of stay for older COVID-19 patients.(2023-02-28T21:00:00Z) Buyukaydin, Banu; Karaaslan, Tahsin; Uysal, Omer; BÜYÜKAYDIN, BANUObjective: This study was intended to research the sensitivity of the Charlson Comorbidity Index (CCI), COVID-GRAM, and MuLBSTA risk scores for hospital length of stay (LOS) and mortality in older patients hospitalized with coronavirus disease 2019 (COVID-19). Methods: A total of 217 patients (119 women) were included in the study. The first clinical signs, comorbidities, laboratory and radiology findings, and hospital LOS were recorded for each patient. The CCI, COVID-GRAM, and MuLBSTA risk scores were calculated, and their sensitivities for hospital LOS and mortality were evaluated using receiver operating characteristic (ROC) curve analysis. Results: Of the hospitalized patients, 59 (27.2%) were followed in the intensive care unit, and mortality developed in 44 (20.3%). The CCI positively correlated with COVID-GRAM and MuLBSTA scores (P < 0.001). COVID-GRAM and MuLBSTA results correlated with LOS and mortality (P < 0.001). According to the ROC curve analysis, the cutoff points for mortality were 5 for CCI, 169 for COVID-GRAM, and 9 for MuLBSTA. Conclusion: Older patients with comorbidities are the major risk group for severe COVID-19. COVID-GRAM and MuLBSTA scores appear to be sensitive and reliable mortality indicators for these patients.